Ko Okumura Selected Research

TNF-Related Apoptosis-Inducing Ligand Receptors

1/2020	Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
12/2011	Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
5/2010	Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
8/2008	Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.
10/2004	Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors.
2/2004	Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ko Okumura Research Topics

Disease

56	Inflammation (Inflammations) 01/2022 - 05/2002
30	Hypersensitivity (Allergy) 01/2021 - 05/2002
28	Neoplasms (Cancer) 02/2022 - 01/2002
18	Asthma (Bronchial Asthma) 01/2021 - 08/2002
17	Atopic Dermatitis (Atopic Eczema) 01/2022 - 12/2002
13	Infections 03/2016 - 06/2003
12	Eosinophilia 01/2021 - 10/2003
10	Wounds and Injuries (Trauma) 01/2022 - 03/2003
10	Colitis 05/2016 - 02/2003
8	type 2C Congenital disorder of glycosylation 01/2022 - 04/2010
8	Contact Dermatitis (Eczema, Contact) 11/2018 - 10/2003
7	Anaphylaxis (Anaphylactic Shock) 01/2018 - 05/2002
7	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2015 - 12/2002
6	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 10/2021 - 07/2002
6	Neoplasm Metastasis (Metastasis) 03/2021 - 09/2003
6	Food Hypersensitivity (Food Allergy) 01/2021 - 06/2005
6	Virus Diseases (Viral Diseases) 05/2018 - 01/2009
6	Necrosis 06/2012 - 01/2002
5	Reperfusion Injury 01/2021 - 12/2005
5	Arthritis (Polyarthritis) 01/2019 - 10/2002
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2011 - 08/2002
5	Rheumatoid Arthritis 03/2010 - 10/2002
5	Skin Diseases (Skin Disease) 01/2009 - 12/2002
4	Hyperplasia 03/2017 - 02/2007
4	Experimental Arthritis 03/2011 - 10/2002
3	Hypoxia (Hypoxemia) 02/2022 - 09/2015
3	Ischemia 01/2021 - 05/2010
3	Fibrosis (Cirrhosis) 12/2020 - 08/2004
3	Ischemic Stroke 01/2019 - 07/2009
3	Leukemia 01/2018 - 05/2002
3	Pneumonia (Pneumonitis) 12/2017 - 09/2012
3	Sepsis (Septicemia) 01/2017 - 05/2002
3	Fibrosarcoma 01/2017 - 10/2005
3	Respiratory Hypersensitivity 01/2015 - 12/2002
3	Autoimmune Diseases (Autoimmune Disease) 01/2015 - 06/2002
3	Hepatitis 12/2012 - 01/2009
3	Disease Progression 08/2009 - 08/2002
3	Myocarditis (Carditis) 07/2007 - 04/2002
3	Chagas Disease (American Trypanosomiasis) 11/2005 - 03/2003

Drug/Important Bio-Agent (IBA)

39	CytokinesIBA 01/2022 - 05/2002
32	Immunoglobulin E (IgE)IBA 01/2021 - 05/2002
25	AllergensIBA 10/2021 - 04/2003
20	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 01/2002
20	LigandsIBA 12/2015 - 01/2002
19	AntigensIBA 01/2021 - 05/2002
18	Monoclonal AntibodiesIBA 01/2022 - 01/2002
17	Proteins (Proteins, Gene)FDA Link 10/2021 - 10/2002
15	Interleukin-33IBA 01/2021 - 12/2009
14	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 01/2002
11	ChemokinesIBA 01/2022 - 12/2002
10	Thymic Stromal LymphopoietinIBA 01/2021 - 05/2007
10	OvalbuminIBA 01/2021 - 04/2003
10	Transforming Growth Factor beta (TGF-beta)IBA 09/2010 - 08/2002
9	TNF-Related Apoptosis-Inducing LigandIBA 01/2020 - 10/2002
8	Immunoglobulin G (IgG)IBA 01/2021 - 10/2002
8	AntibodiesIBA 01/2021 - 05/2002
7	PapainIBA 01/2021 - 05/2013
7	IgE Receptors (Fc epsilon RI)IBA 12/2020 - 07/2002
6	Therapeutic UsesIBA 01/2022 - 09/2003
6	Peptides (Polypeptides)IBA 01/2022 - 06/2005
6	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2020 - 02/2004
6	Dermatophagoides pteronyssinus antigen p 1IBA 12/2011 - 07/2005
5	Interleukin-13IBA 12/2020 - 10/2003
5	Messenger RNA (mRNA)IBA 11/2019 - 10/2003
4	Apoptosis Regulatory ProteinsIBA 12/2021 - 11/2016
4	Pharmaceutical PreparationsIBA 03/2021 - 03/2003
4	Interleukin-17 (Interleukin 17)IBA 01/2021 - 10/2012
4	Interleukin-1 (Interleukin 1)IBA 11/2019 - 10/2010
4	Interleukin-4 (Interleukin 4)IBA 11/2019 - 10/2003
4	HaptensIBA 11/2018 - 10/2003
4	VaccinesIBA 01/2018 - 03/2009
4	Dextrans (Dextran)FDA Link 05/2016 - 08/2010
4	Interleukin-10 (Interleukin 10)IBA 07/2013 - 10/2003
4	Dermatophagoides farinae antigen f 1IBA 05/2013 - 07/2005
4	Neutralizing AntibodiesIBA 12/2012 - 06/2005
4	MucinsIBA 03/2011 - 02/2007
4	Thromboplastin (Tissue Factor)IBA 02/2011 - 07/2009
4	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2009 - 01/2003
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2021 - 01/2016
3	EnzymesIBA 02/2021 - 01/2007
3	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2020 - 05/2002
3	Interleukin-2 (IL2)IBA 01/2020 - 10/2003
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 08/2002
3	CeramidesIBA 01/2017 - 05/2016
3	sodium sulfate (sodium bisulfate)FDA LinkGeneric 05/2016 - 08/2010
3	Tretinoin (Retinoic Acid)FDA LinkGeneric 03/2015 - 10/2012
3	CollagenIBA 11/2013 - 12/2005
3	Fas Ligand Protein (Fas Ligand)IBA 12/2012 - 01/2005
3	InterferonsIBA 12/2012 - 01/2002
3	Phosphotransferases (Kinase)IBA 08/2011 - 02/2007
3	Collagen Type II (Type II Collagen)IBA 05/2007 - 10/2002
2	DNA (Deoxyribonucleic Acid)IBA 02/2022 - 06/2003
2	S100 Calcium Binding Protein A7IBA 02/2022 - 07/2008
2	Conditioned Culture MediaIBA 02/2022 - 09/2015
2	Tyrosine (L-Tyrosine)FDA Link 02/2022 - 09/2015
2	Streptozocin (Streptozotocin)FDA Link 01/2022 - 10/2010

Therapy/Procedure

14	Therapeutics 02/2022 - 08/2002
14	Immunotherapy 01/2021 - 04/2002
3	Ligation 01/2017 - 04/2005
3	Oral Administration 01/2008 - 06/2005